Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/187024
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | González-Juanatey, J. R. | - |
dc.contributor.author | Anguita Sánchez, Manuel | - |
dc.contributor.author | Bayés Genís, Antoni | - |
dc.contributor.author | Comín Colet, Josep | - |
dc.contributor.author | García Quintana, Antonio | - |
dc.contributor.author | Recio Mayoral, A. | - |
dc.contributor.author | Zamorano Gómez, José Luis | - |
dc.contributor.author | Cepeda Rodrigo, J.M. | - |
dc.contributor.author | Manzano, L. | - |
dc.date.accessioned | 2022-06-27T08:45:46Z | - |
dc.date.available | 2022-06-27T08:45:46Z | - |
dc.date.issued | 2022-02-01 | - |
dc.identifier.issn | 2254-8874 | - |
dc.identifier.uri | http://hdl.handle.net/2445/187024 | - |
dc.description.abstract | Despite currently available treatments, risk of death and hospitalizations in patients with heart failure with reduced ejection fraction (HFrEF) remains high. The pathophysiology of HFrEF includes neurohormonal activation characterized by stimulation of deleterious pathways (i.e., sympathetic nervous and renin-angiotensin-aldosterone systems) and suppression of pro-tective pathways such as nitric oxide-dependent pathways. Inhibition or stimulation of some, but not all, of these pathways is insufficient. In HFrEF, there is reduced nitric oxide, soluble guanylate cyclase, and cGMP activity, leading to deleterious effects in the myocardial, vascu-lar, and renal systems. Vericiguat is able to stimulate the activity of this protective pathway. The VICTORIA study demonstrated that the addition of vericiguat to optimal medical treatment in patients with HFrEF and recent decompensation significantly reduced the incidence of the primary endpoint, a composite of cardiovascular death or HF hospitalization, with a number needed to treat of 24 patients and excellent tolerability. | - |
dc.format.extent | 11 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Elsevier BV | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.1016/j.rce.2021.12.005 | - |
dc.relation.ispartof | Revista Clínica Española, 2022, vol. 222, num. 6, p. 359-369 | - |
dc.relation.uri | https://doi.org/10.1016/j.rce.2021.12.005 | - |
dc.rights | cc by (c) González Juanatey, J.R. et al., 2022 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es/ | * |
dc.source | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) | - |
dc.subject.classification | Insuficiència cardíaca | - |
dc.subject.classification | Farmacologia cardiovascular | - |
dc.subject.other | Heart failure | - |
dc.subject.other | Cardiovascular pharmacology | - |
dc.title | Vericiguat en insuficiencia cardíaca: de la evidencia científica a la práctica clínica | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.date.updated | 2022-06-23T13:08:22Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 35473692 | - |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
1-s2.0-S0014256522000030-main.pdf | 1.22 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License